SCHEMBL11898667

SCHEMBL11898667

Oc1ccccc1/C=N/Nc1nc(Nc2ccc(F)cc2)nc(Nc2ccc(F)cc2)n1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.83
▸ MAPT P10636 5/20 0.83
▸ KDM4E B2RXH2 4/20 0.83
▸ MEN1 O00255 4/20 0.83
▸ HTT P42858 4/20 0.83
▸ TDP1 Q9NUW8 2/20 0.83
▸ POLB P06746 1/20 0.83
▸ BLM P54132 1/20 0.83
▸ DDX3X O00571 8/20 0.67
▸ CA12 O43570 3/20 0.57
▸ CA1 P00915 3/20 0.57
▸ CA2 P00918 3/20 0.57
▸ CA9 Q16790 3/20 0.57
▸ NPSR1 Q6W5P4 3/20 0.54
▸ LMNA P02545 2/20 0.54
▸ USP2 O75604 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ GAA P10253 3/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ HPGD P15428 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11898668 1.00 KMT2A (0.83) KMT2AMAPTKDM4EMEN1HTT
SCHEMBL11899415 0.85 MAPT (0.64) KMT2AMAPTKDM4EMEN1HTT
SCHEMBL11899414 0.85 MAPT (0.64) KMT2AMAPTKDM4EMEN1HTT
SCHEMBL1658047 0.81 DDX3X (1.00) KMT2AMAPTKDM4EMEN1HTT
SCHEMBL11899536 0.81 DDX3X (1.00) KMT2AMAPTKDM4EMEN1HTT
SCHEMBL22903887 0.79 KDM4E (0.74) KMT2AMAPTKDM4EMEN1HTT
SCHEMBL19434689 0.77 KDM4E (0.58) KMT2AMAPTKDM4EMEN1HTT
SCHEMBL19434692 0.77 KDM4E (0.58) KMT2AMAPTKDM4EMEN1HTT
SCHEMBL6421066 0.77 KMT2A (0.54) KMT2AMAPTKDM4EMEN1HTT
SCHEMBL11913667 0.76 DDX3X (1.00) KMT2AMAPTKDM4EMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120202814-A1 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF UNIVERSITÀ DEGLI STUDI DI SIENA (IT) 2012-08-09 — — US disclosed
US-20120202814-A1 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF UNIVERSITÀ DEGLI STUDI DI SIENA (IT) 2012-08-09 — — US disclosed
US-20120202814-A1 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF UNIVERSITÀ DEGLI STUDI DI SIENA (IT) 2012-08-09 — — US disclosed
WO-2011039735-A2 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 2011-04-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202814-A1 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF DDX3X, DDX21, DDX39B KMT2A 2610/4885MAPT 4074/4885KDM4E 2477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback